Radioactive drug combo shows promise for advanced prostate cancer

NCT ID NCT03361735

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This phase 2 trial is testing a combination of radium-223 (a radioactive drug that targets bone tumors), hormone therapy, and precise radiation for men with prostate cancer that has spread to a few other places in the body. The goal is to see if this triple approach can delay cancer progression better than standard treatments. The study enrolled 25 participants and is no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
Radium Ra 223 dichloride (a radioactive drug that targets bone tumors)
What this could lead to
If successful, this combination could offer a new way to delay cancer progression in men with prostate cancer that has spread to a few spots in the body.
What could go wrong
This is a small, early-phase trial with only 25 participants, so results may not apply to everyone. The treatment involves radiation and hormone therapy, which can cause side effects like fatigue, bone pain, and hormonal changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OLIGOMETASTATIC CASTRATION SENSITIVE PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.